Resurgence of congenital syphilis signals ‘urgent need’ for testing, treatment

A poster of pregnancy in an examination room at Marys Center on March 17, 2023, in Washington, D.C. Congenital syphilis is usually devastating to babies but is preventable through testing and treatment during pregnancy.

A poster of pregnancy in an examination room at Marys Center on March 17, 2023, in Washington, D.C. Congenital syphilis is usually devastating to babies but is preventable through testing and treatment during pregnancy. Bonnie Jo Mount/The Washington Post via Getty Images

 

Connecting state and local government leaders

Congenital syphilis cases have increased significantly nationwide. They're highest are highest in parts of the Southwest, the Midwest and the South.

This story was originally published by Healthbeat. Sign up for their public health newsletters at healthbeat.org/newsletters.

Public health officials in New York are urgently promoting syphilis testing and treatment, alarmed that a preventable sexually transmitted infection once close to eradication has returned.

They are especially concerned about a resurgence of congenital syphilis, which is passed from a pregnant person to a baby. Congenital syphilis can result in miscarriage, stillbirth, prematurity and infant death, and babies born with the infection can have deformed bones, severe anemia, brain and nerve problems, and other issues.

In recent years, congenital syphilis cases have increased significantly nationwide, rising from 334 cases reported in 2012 to 3,761 in 2022, according to data from the Centers for Disease Control and Prevention. The CDC reported 231 stillbirths and 51 infant deaths in 2022.

Those outcomes are particularly distressing, experts say, because congenital syphilis is preventable and can be treated relatively easily, with a form of penicillin. But cases can emerge when pregnant people aren’t tested for syphilis at key intervals, or if they don’t have access to prenatal care.

Funding for the CDC’s prevention programs for sexually transmitted infections has been relatively flat over the past two decades, and recently, some local health departments across the country have faced steep cuts in their budgets for prevention efforts.

“We are all very concerned, as clinicians, about the increases in congenital syphilis, and syphilis in general, across the United States,” said Dr. Rodney Wright, vice chair of obstetrics at Montefiore Medical Center in the Bronx. “It’s not just a problem here in New York. It’s a problem across the entire nation.”

Congenital syphilis rates are highest in parts of the Southwest, the Midwest and the South. Native American communities have been hit particularly hard. But even in New York, which has among the lowest rates of congenital syphilis in the country, mounting cases have raised alarms.

New York is just above the national average for rates of primary and secondary syphilis — the most infectious stages of the disease — which can result in congenital cases.

Preliminary data for 2023 show about 70 congenital syphilis diagnoses in New York state, a 204% increase over the past decade, Joseph Kerwin, director of the AIDS Institute at the New York State Department of Health, said during a meeting of the New York State AIDS Advisory Council in September.

“This is the first time in this century that New York state has seen a number rise to this level,” Kerwin said of the cases.

This year, New York is on track to see at least the same number of congenital syphilis cases as last year, said Rachel Malloy, director of the Office of Sexual Health and Epidemiology at the AIDS Institute.

“Compared to the rest of the country, New York state rates are actually lower, which speaks to the magnitude of the issue, because the rates in New York state are high,” Malloy said.

Surge in Primary and Secondary Syphilis Drives Congenital Cases

When the CDC began tracking syphilis cases in the 1940s, the agency regularly recorded hundreds of thousands of total cases each year nationwide.

But by 2000, total syphilis cases had dropped to 31,618 — and just 5,979 cases of primary and secondary syphilis. That year, the rate of primary and secondary syphilis fell to its lowest point since reporting began in 1941 (2.1 cases per 100,000 people).

That data point reflected a significant achievement in the country’s fight to eliminate syphilis, which is often called “the great imitator” due to its frustratingly wide range of symptoms. At its primary stage, the infection is easy to miss, often appearing as a single, painless sore. By the secondary stage, symptoms can include a skin rash, sores, fever, muscle aches and hair loss. Left untreated, syphilis can damage the brain, heart, and other organs, and the infection can be fatal.

“We were on the verge of eliminating syphilis altogether about 20 years ago, 25 years ago,” said Preeti Pathela, executive director of the Sexually Transmitted Infections Program in the Bureau of Hepatitis, HIV, and STI at the New York City Department of Health and Mental Hygiene. “We’ve seen a rise in adult syphilis since that time.”

By 2022, the total number of syphilis cases nationwide had surged to more than 200,000. Primary and secondary syphilis cases increased to more than 59,000 (17.7 cases per 100,000 people). Over the decades, rates of primary and secondary syphilis among women have increased, a key driver of congenital cases.

In New York City, the Health Department reported a 35% increase from 2021 to 2022 in primary and secondary syphilis cases among women — primarily among Black and Latina women — but little change among men. The agency reported 19 cases of congenital syphilis across the city in 2022 — and 16 cases in just the first half of 2023, according to the agency’s preliminary data.

“It is clear that there’s been a dramatic increase here,” Pathela said.

Earlier this year, the Health Department released an advisory for health care providers warning of “alarming rates” of primary and secondary syphilis and congenital syphilis in the city, “signaling an urgent need for increased screening and appropriate treatment.”

“There has been, for a long time, a real misconception about risk, both in the community, but also among health care providers, that you don’t need to screen or test if someone doesn’t report individual risk behaviors, or sexual behaviors that might put them at risk of acquiring syphilis,” Pathela said.

For many sexually active people, living in a community with a high rate of syphilis poses a significant risk factor for acquiring the infection, she said. In 2022, the Bronx had the highest rate of primary and secondary syphilis among women ages 15 to 44 (22.5 cases per 100,000 people), followed by Brooklyn (11.4 cases per 100,000 people).

“The disproportionate burden of primary and secondary syphilis among Black and Latina and young females often reflects the impact of structural racism,” Pathela added. “That prevents many people of color from accessing care, and especially affordable care.”

Experts Urge Expanding Syphilis Testing, Treatment

The United States has reduced surges of congenital syphilis cases before — most recently in the 1990s — and experts say it can be done again.

The solution is clear, they say: closing gaps in testing and treatment. In 2022, lack of timely testing and adequate treatment contributed to almost 90% of congenital syphilis cases across the country, according to the CDC.

“The biggest part of addressing this issue is making sure people are tested and treated,” Wright, the Montefiore physician, said. “I think there may have been a bit of complacency about syphilis for a number of years.”

In New York, a new state requirement went into effect this spring which mandates a syphilis test during the third trimester of pregnancy, in addition to screening at first exam and delivery. (New York City has required third trimester syphilis testing since 2019.)

A state strategic planning group is poised to release a series of recommendations to guide New York’s efforts to reduce and eliminate congenital syphilis. And state and city officials have ramped up warnings to health providers, who may have little firsthand experience with congenital syphilis.

Over the course of his 25 year career, Wright said, congenital syphilis cases were rare — but have increased in recent years.

During the September AIDS Advisory Council meeting, he described a recent case that resulted in a neonatal death. The pregnant person, he said, had tested negative at the beginning of pregnancy but had not reached the point of third trimester testing.

The late identification of syphilis during pregnancy has been a major missed opportunity in nationwide and state prevention efforts, officials say.

Malloy, of the AIDS Institute, stressed the importance of determining the pregnancy status of any individual of reproductive capacity diagnosed with syphilis — and expanding access to prenatal care for pregnant people.

Disrupting networks of transmission is key, too. While reviewing congenital syphilis cases in the city and state, Wright noticed that in some cases, partners who were not tested or declined treatment reinfected the pregnant person.

“That drives home the point of partner notification and encouraging partner testing and treatment,” he said.

The state employs contact tracers and case investigators who follow up with people newly diagnosed with STIs and maintains a call line for providers working on congenital syphilis cases, Malloy noted.

New York City’s STI Disease Intervention Specialists work to find people who need STI treatment and help notify partners. In 2022, they conducted more than 14,000 case investigations based on positive syphilis laboratory tests. The Health Department also identified 196 cases of congenital syphilis, estimating that it averted 91% of potential cases.

“I am hopeful,” Malloy said. “We have seen syphilis and congenital syphilis go down before. I want to see it go down, and I want to see it stay down. And I do think that if we act now and act together, we will get those numbers down.”

Healthbeat is a nonprofit news platform reporting on public health from Civic News Company and KFF Health News.

X
This website uses cookies to enhance user experience and to analyze performance and traffic on our website. We also share information about your use of our site with our social media, advertising and analytics partners. Learn More / Do Not Sell My Personal Information
Accept Cookies
X
Cookie Preferences Cookie List

Do Not Sell My Personal Information

When you visit our website, we store cookies on your browser to collect information. The information collected might relate to you, your preferences or your device, and is mostly used to make the site work as you expect it to and to provide a more personalized web experience. However, you can choose not to allow certain types of cookies, which may impact your experience of the site and the services we are able to offer. Click on the different category headings to find out more and change our default settings according to your preference. You cannot opt-out of our First Party Strictly Necessary Cookies as they are deployed in order to ensure the proper functioning of our website (such as prompting the cookie banner and remembering your settings, to log into your account, to redirect you when you log out, etc.). For more information about the First and Third Party Cookies used please follow this link.

Allow All Cookies

Manage Consent Preferences

Strictly Necessary Cookies - Always Active

We do not allow you to opt-out of our certain cookies, as they are necessary to ensure the proper functioning of our website (such as prompting our cookie banner and remembering your privacy choices) and/or to monitor site performance. These cookies are not used in a way that constitutes a “sale” of your data under the CCPA. You can set your browser to block or alert you about these cookies, but some parts of the site will not work as intended if you do so. You can usually find these settings in the Options or Preferences menu of your browser. Visit www.allaboutcookies.org to learn more.

Sale of Personal Data, Targeting & Social Media Cookies

Under the California Consumer Privacy Act, you have the right to opt-out of the sale of your personal information to third parties. These cookies collect information for analytics and to personalize your experience with targeted ads. You may exercise your right to opt out of the sale of personal information by using this toggle switch. If you opt out we will not be able to offer you personalised ads and will not hand over your personal information to any third parties. Additionally, you may contact our legal department for further clarification about your rights as a California consumer by using this Exercise My Rights link

If you have enabled privacy controls on your browser (such as a plugin), we have to take that as a valid request to opt-out. Therefore we would not be able to track your activity through the web. This may affect our ability to personalize ads according to your preferences.

Targeting cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.

Social media cookies are set by a range of social media services that we have added to the site to enable you to share our content with your friends and networks. They are capable of tracking your browser across other sites and building up a profile of your interests. This may impact the content and messages you see on other websites you visit. If you do not allow these cookies you may not be able to use or see these sharing tools.

If you want to opt out of all of our lead reports and lists, please submit a privacy request at our Do Not Sell page.

Save Settings
Cookie Preferences Cookie List

Cookie List

A cookie is a small piece of data (text file) that a website – when visited by a user – asks your browser to store on your device in order to remember information about you, such as your language preference or login information. Those cookies are set by us and called first-party cookies. We also use third-party cookies – which are cookies from a domain different than the domain of the website you are visiting – for our advertising and marketing efforts. More specifically, we use cookies and other tracking technologies for the following purposes:

Strictly Necessary Cookies

We do not allow you to opt-out of our certain cookies, as they are necessary to ensure the proper functioning of our website (such as prompting our cookie banner and remembering your privacy choices) and/or to monitor site performance. These cookies are not used in a way that constitutes a “sale” of your data under the CCPA. You can set your browser to block or alert you about these cookies, but some parts of the site will not work as intended if you do so. You can usually find these settings in the Options or Preferences menu of your browser. Visit www.allaboutcookies.org to learn more.

Functional Cookies

We do not allow you to opt-out of our certain cookies, as they are necessary to ensure the proper functioning of our website (such as prompting our cookie banner and remembering your privacy choices) and/or to monitor site performance. These cookies are not used in a way that constitutes a “sale” of your data under the CCPA. You can set your browser to block or alert you about these cookies, but some parts of the site will not work as intended if you do so. You can usually find these settings in the Options or Preferences menu of your browser. Visit www.allaboutcookies.org to learn more.

Performance Cookies

We do not allow you to opt-out of our certain cookies, as they are necessary to ensure the proper functioning of our website (such as prompting our cookie banner and remembering your privacy choices) and/or to monitor site performance. These cookies are not used in a way that constitutes a “sale” of your data under the CCPA. You can set your browser to block or alert you about these cookies, but some parts of the site will not work as intended if you do so. You can usually find these settings in the Options or Preferences menu of your browser. Visit www.allaboutcookies.org to learn more.

Sale of Personal Data

We also use cookies to personalize your experience on our websites, including by determining the most relevant content and advertisements to show you, and to monitor site traffic and performance, so that we may improve our websites and your experience. You may opt out of our use of such cookies (and the associated “sale” of your Personal Information) by using this toggle switch. You will still see some advertising, regardless of your selection. Because we do not track you across different devices, browsers and GEMG properties, your selection will take effect only on this browser, this device and this website.

Social Media Cookies

We also use cookies to personalize your experience on our websites, including by determining the most relevant content and advertisements to show you, and to monitor site traffic and performance, so that we may improve our websites and your experience. You may opt out of our use of such cookies (and the associated “sale” of your Personal Information) by using this toggle switch. You will still see some advertising, regardless of your selection. Because we do not track you across different devices, browsers and GEMG properties, your selection will take effect only on this browser, this device and this website.

Targeting Cookies

We also use cookies to personalize your experience on our websites, including by determining the most relevant content and advertisements to show you, and to monitor site traffic and performance, so that we may improve our websites and your experience. You may opt out of our use of such cookies (and the associated “sale” of your Personal Information) by using this toggle switch. You will still see some advertising, regardless of your selection. Because we do not track you across different devices, browsers and GEMG properties, your selection will take effect only on this browser, this device and this website.